rs35654345
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 2P and 3B. PM2BP4_ModerateBP6
The NM_000558.5(HBA1):c.341T>A(p.Leu114His) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000342 in 1,460,452 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another nucleotide change resulting in the same amino acid substitution has been previously reported as Likely benign in UniProt.
Frequency
Consequence
NM_000558.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -1 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000658 AC: 1AN: 152004Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000203 AC: 5AN: 246076Hom.: 0 AF XY: 0.0000224 AC XY: 3AN XY: 133818
GnomAD4 exome AF: 0.00000342 AC: 5AN: 1460452Hom.: 0 Cov.: 32 AF XY: 0.00000413 AC XY: 3AN XY: 726522
GnomAD4 genome Data not reliable, filtered out with message: AS_VQSR AF: 0.00000658 AC: 1AN: 152004Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74230
ClinVar
Submissions by phenotype
not provided Uncertain:1Benign:1
The Hb Twin Peaks variant (HBA1: c.341T>A; p.Leu114His, also known as Leu113His when numbered from the mature protein; rs35654345, HbVarID: 175) is reported in the literature as a stable hemoglobin variant and is not associated with clinical symptoms in a heterozygous state (HbVar database and references therein). In vitro studies also demonstrate that this variant increases the solubility of Hb S when forming the globin tetramer, potentially acting as an inhibitor of polymerization (Sivaram 2001). This variant is reported in ClinVar (Variation ID: 15829). This variant is found in the Latino population with an allele frequency of 0.0146% (5/34326 alleles), in the Genome Aggregation Database. Computational analyses are uncertain whether this variant is neutral or deleterious (REVEL: 0.376). Based on available information, the Hb Twin Peaks variant is considered to be likely benign. References: Link to HbVar database: https://globin.bx.psu.edu/hbvar/menu.html Sivaram M et al. A role for the alpha 113 (GH1) amino acid residue in the polymerization of sickle hemoglobin. Evaluation of its inhibitory strength and interaction linkage with two fiber contact sites (alpha 16/23) located in the AB region of the alpha-chain. J Biol Chem. 2001; 276(21):18209-15. PMID: 11259442. -
The HBA1 c.341T>A (p.Leu114His) variant (also known as Hb Twin Peaks) has been reported to have normal stability, and individuals who are heterozygous for this variant have a normal clinical presentation (HbVar (http://globin.cse.psu.edu/cgi-bin/hbvar/counter) and PMID: 3839772 (1985)). This variant has been found to have anti-sickling effect when in association with HbS (PMID: 11259442 (2001)). Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant. -
HBA1-related disorder Uncertain:1
The HBA1 c.341T>A variant is predicted to result in the amino acid substitution p.Leu114His. To our knowledge, this variant has not been reported in the literature in association with disease. This variant is reported in 0.015% of alleles in individuals of Latino descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -
HEMOGLOBIN TWIN PEAKS Other:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at